Skip to main content
Evidence Snapshot

Prothrombin

CHEMBL204 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:06:23Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL204
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Prothrombin as ChEMBL target CHEMBL204, mapped to UniProt P00734. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Prothrombin
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL204
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P00734
Prothrombin
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Prothrombin matters

As of 2026-09-13

Prothrombin is reviewed as Prothrombin (UniProt P00734); Prothrombin shows approved-linked disease relevance led by Recurrent thrombophlebitis. 5 more disease programs remain visible in the same review block.; 6 linked drugs keep this evidence frame grounded.; the current evidence base includes 16 approved drugs, 10665 compounds, and 1194 assays, with lead potency reaching pChEMBL 11.0.

Disease context
Recurrent thrombophlebitis

Prothrombin shows approved-linked disease relevance led by Recurrent thrombophlebitis. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ARGATROBAN, BIVALIRUDIN, DEFIBROTIDE.

Start review with Recurrent thrombophlebitis because it currently carries approved-linked support. Linked drugs include ARGATROBAN, BIVALIRUDIN, DEFIBROTIDE, DESIRUDIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 6 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 16 approved drugs, 10665 compounds, and 1194 assays for this target. The dominant activity type is KI. CHEMBL121212 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL121212 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
16 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Prothrombin matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P00734, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Recurrent thrombophlebitis is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

10665
Total Compounds
1194
Total Assays
16
Approved Drugs
IC50: 3807.0, KI: 5401.0, EC50: 16.0, KD: 65.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL121212
 11.0 Ki —
No preferred name
CHEMBL120079
 11.0 Ki —
No preferred name
CHEMBL4108739
 11.0 IC50 —
No preferred name
CHEMBL285285
 11.0 Ki —
No preferred name
CHEMBL323583
 10.9 Ki —

Approved Drugs

Structure Compound First Approval
BETRIXABAN
CHEMBL512351
 2017
DABIGATRAN ETEXILATE
CHEMBL539697
 2008
MELAGATRAN
CHEMBL266349
 2004
ARGATROBAN
CHEMBL1166
 2000
CAPTOPRIL
CHEMBL1560
 1981
LIOTHYRONINE
CHEMBL1544
 1956
SULFAGUANIDINE
CHEMBL338802
 —
XIMELAGATRAN
CHEMBL522038
 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:06:23Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL204